Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
$91.22
+1.4%
$94.12
$79.52
$124.00
$23.07B1.321.07 million shs873,543 shs
Moderna, Inc. stock logo
MRNA
Moderna
$67.27
+12.6%
$51.26
$22.28
$69.29
$23.71B1.059.23 million shs14.44 million shs
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
$279.89
+1.7%
$291.75
$239.25
$385.22
$30.71B0.49260,748 shs336,792 shs
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
$327.79
0.0%
$314.27
$37.19
$366.52
$9.14B2.71488,008 shs2.06 million shs
7 Stocks to Buy And Hold Forever Cover

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
-0.23%-0.98%-2.44%+5.04%-14.12%
Moderna, Inc. stock logo
MRNA
Moderna
-1.11%-6.58%+27.05%+20.56%+122.45%
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
-0.64%+1.92%-9.01%-2.72%+3.07%
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
+6.12%+16.13%-6.49%+13.02%+656.66%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
$91.22
+1.4%
$94.12
$79.52
$124.00
$23.07B1.321.07 million shs873,543 shs
Moderna, Inc. stock logo
MRNA
Moderna
$67.27
+12.6%
$51.26
$22.28
$69.29
$23.71B1.059.23 million shs14.44 million shs
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
$279.89
+1.7%
$291.75
$239.25
$385.22
$30.71B0.49260,748 shs336,792 shs
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
$327.79
0.0%
$314.27
$37.19
$366.52
$9.14B2.71488,008 shs2.06 million shs
7 Stocks to Buy And Hold Forever Cover

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
-0.23%-0.98%-2.44%+5.04%-14.12%
Moderna, Inc. stock logo
MRNA
Moderna
-1.11%-6.58%+27.05%+20.56%+122.45%
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
-0.64%+1.92%-9.01%-2.72%+3.07%
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
+6.12%+16.13%-6.49%+13.02%+656.66%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
2.74
Moderate Buy$129.5642.03% Upside
Moderna, Inc. stock logo
MRNA
Moderna
1.83
Reduce$37.13-44.80% Downside
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
2.93
Moderate Buy$390.0039.34% Upside
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
2.95
Moderate Buy$566.2172.74% Upside

Current Analyst Ratings Breakdown

Latest PRAX, ONC, MRNA, and BNTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/26/2026
Moderna, Inc. stock logo
MRNA
Moderna
Boost Price TargetOverweight$69.00 ➝ $77.00
6/18/2026
Moderna, Inc. stock logo
MRNA
Moderna
Reiterated RatingHold
6/17/2026
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
Initiated CoverageOutperform$449.00
6/17/2026
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
UpgradeModerate Buy
6/12/2026
Moderna, Inc. stock logo
MRNA
Moderna
Reiterated RatingSell (D-)
6/8/2026
Moderna, Inc. stock logo
MRNA
Moderna
Boost Price TargetUnderperform$32.00 ➝ $34.00
6/5/2026
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
Reiterated RatingMarket Perform
6/4/2026
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
UpgradeHoldStrong-Buy
6/2/2026
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
Reiterated RatingBuy
6/2/2026
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
Set Price TargetBuy$715.00 ➝ $616.00
6/2/2026
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
Reiterated RatingOutperform$750.00 ➝ $650.00
(Data available from 6/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
$3.25B7.11$1.35 per share67.57$96.59 per share0.94
Moderna, Inc. stock logo
MRNA
Moderna
$2.20B12.11N/AN/A$22.14 per share3.04
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
$5.34B5.75$3.95 per share70.90$39.77 per share7.04
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
$8.55M1,068.86N/AN/A$34.85 per share9.41
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
-$1.29B-$5.88N/AN/AN/A-44.39%-5.30%-4.62%8/4/2026 (Estimated)
Moderna, Inc. stock logo
MRNA
Moderna
-$2.82B-$8.15N/AN/AN/A-143.55%-26.64%-19.32%7/31/2026 (Estimated)
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
$286.93M$4.4762.6226.50N/A8.94%12.06%6.69%N/A
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
-$303.27M-$13.37N/AN/AN/AN/A-43.02%-40.22%8/3/2026 (Estimated)

Latest PRAX, ONC, MRNA, and BNTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2026Q1 2026
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
-$3.58-$3.20+$0.38-$3.20$0.10 millionN/A
5/4/2026Q1 2026
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
-$2.52-$2.2570+$0.2630-$2.43$207.42 million$136.71 million
5/1/2026Q1 2026
Moderna, Inc. stock logo
MRNA
Moderna
-$3.02-$3.40-$0.38-$3.40$236.37 million$389.00 million
4/1/2026Q1 2026
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
N/A$0.25N/A$1.95N/A$1.51 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
N/AN/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
N/AN/AN/AN/AN/A
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
0.01
8.80
8.74
Moderna, Inc. stock logo
MRNA
Moderna
0.08
2.41
2.35
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
0.20
3.64
3.27
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
N/A
15.88
15.88

Institutional Ownership

CompanyInstitutional Ownership
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
15.52%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
48.55%
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
67.84%

Insider Ownership

CompanyInsider Ownership
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
19.20%
Moderna, Inc. stock logo
MRNA
Moderna
10.80%
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
6.19%
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
3.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
7,807252.88 million204.33 millionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
4,700396.79 million353.93 millionOptionable
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
12,000109.72 million102.93 millionN/A
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
11027.88 million27.04 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
BioNTech stock logo

BioNTech NASDAQ:BNTX

$91.22 +1.22 (+1.36%)
Closing price 04:00 PM Eastern
Extended Trading
$90.75 -0.47 (-0.51%)
As of 07:18 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Moderna stock logo

Moderna NASDAQ:MRNA

$67.27 +7.52 (+12.59%)
Closing price 04:00 PM Eastern
Extended Trading
$67.12 -0.15 (-0.22%)
As of 07:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

BeOne Medicines stock logo

BeOne Medicines NASDAQ:ONC

$279.89 +4.55 (+1.65%)
Closing price 04:00 PM Eastern
Extended Trading
$280.14 +0.25 (+0.09%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Praxis Precision Medicines stock logo

Praxis Precision Medicines NASDAQ:PRAX

$327.79 -0.07 (-0.02%)
Closing price 04:00 PM Eastern
Extended Trading
$329.68 +1.89 (+0.58%)
As of 06:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.